{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:05:24Z","timestamp":1795215924226,"version":"4.10.3"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of two combination treatments for hepatocellular carcinoma (HCC): 1) transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) combined with molecular targeted therapies (MTTs) and immune checkpoint inhibitors (ICIs) (TACE-HAIC-MI), and 2) TACE combined with MTTs and ICIs (TACE-MI). In addition, analysis of changes in serum AFP levels and patient survival was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective study of 459 HCC patients treated with one of the aforementioned treatments was performed: TACE-MI (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      =\u00a0305) and TACE-HAIC-MI (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      =\u00a0154). Inverse probability of treatment weighting (IPTW) was used to minimize confounding factors, and sensitivity analyses were conducted. The joint latent class model was used to model AFP change trajectories, and Cox regression analysis was used to identify prognostic factors. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. Tumor response and adverse events (AEs) were assessed using RECIST v1.1 and CTCAE v5.0, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After IPTW, the median OS of the TACE-HAIC-MI group was 23.9\u00a0months, and for the TACE-MI group it was 21.7\u00a0months(\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.432). The median PFS of the two groups was 9.77\u00a0months versus 8.97\u00a0months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.45). Six optimal latent classes of AFP trajectories were identified. Class 1 demonstrated a median OS of 20.43\u00a0months, while class 2 did not reach the median OS. The median OS for class 3 was 43.87\u00a0months, for class 4 was 18.47\u00a0months, for class 5 was 8.13\u00a0months, and for class 6 was 11.37\u00a0months. Cox regression analyses showed that AFP trajectory independently predicted median OS and PFS, with HRs between 1.56 and 45.28. The most common AEs were elevated transaminase levels, electrolyte imbalances, anemia, and pain. Nausea and vomiting were more frequent in the TACE-HAIC-MI group, and elevated transaminase levels were less common than in the TACE-MI group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TACE-HAIC-MI and TACE-MI treatments have no significant survival differences in patients with HCC. Patients with a favorable AFP response have significantly better survival outcomes than those with a poor response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002818","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:00:08Z","timestamp":1750428008000},"page":"7041-7052","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP"],"prefix":"10.1097","volume":"111","author":[{"given":"Wenli","family":"Li","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Guangzhou Institute of Cancer Research, Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Shantou Central Hospital, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20260109","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.3390\/ijms25136830","article-title":"Advancements in immunotherapeutic treatments for hepatocellular carcinoma: potential of combination therapies","volume":"25","author":"Zarlashat","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R4-20260109","first-page":"3303\u201311","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study","volume":"109","author":"Deng","year":"2023","journal-title":"Int J Surg Lond Engl"},{"key":"R5-20260109","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"8669\u201381","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"eClinicalMedicine"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"1298122","DOI":"10.3389\/fonc.2024.1298122","article-title":"The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"599\u2013616","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"613\u201325","DOI":"10.3892\/or.2016.4842","article-title":"Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians (review)","volume":"36","author":"Reichl","year":"2016","journal-title":"Oncol Rep"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00423-025-03650-7","article-title":"Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection","volume":"410","author":"Qiu","year":"2025","journal-title":"Langenbecks Arch Surg"},{"key":"R13-20260109","article-title":"Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: a multi-institutional analysis","author":"Yao","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"304\u201313","DOI":"10.1016\/j.clgc.2019.11.013","article-title":"Prognostic significance of inflammation-associated blood cell markers in nonmetastatic clear cell renal cell carcinoma","volume":"18","author":"Lee","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"101980","DOI":"10.1016\/j.gassur.2025.101980","article-title":"Hiroshima Surgical Study Group of Clinical Oncology (HiSCO), cluster analysis of HCC prognosis using preoperative AFP and DCP levels: a multi-institutional study","volume":"29","author":"Saegusa","year":"2025","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"2073\u201382","DOI":"10.2147\/JHC.S439660","article-title":"Prognosis prediction of CRAFITY score in HCC undergoing TACE combined with PD-(L)1 inhibitors and molecular targeted therapy","volume":"10","author":"Hu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"R17-20260109","first-page":"353\u201363","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy \u2013 development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"key":"R18-20260109","article-title":"Dynamic changes of serum \u03b1-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma","author":"Yang","journal-title":"Int J Surg"},{"key":"R19-20260109","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1097\/JS9.0000000000001268","article-title":"The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional, and case\u2013control studies in surgery","volume":"110","author":"Rashid","year":"2024","journal-title":"Int J Surg"},{"key":"R21-20260109","first-page":"1\u201323","article-title":"ipw: an R package for inverse probability weighting","volume":"43","author":"van der Wal","year":"2011","journal-title":"J Stat Softw"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1\u201356","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: the R package lcmm","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"J Stat Softw"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"3975\u201388","DOI":"10.3748\/wjg.v26.i27.3975","article-title":"Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma","volume":"26","author":"Guo","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"2321\u201331","DOI":"10.3748\/wjg.v30.i17.2321","article-title":"Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma","volume":"30","author":"Lin","year":"2024","journal-title":"World J Gastroenterol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"1410767","DOI":"10.3389\/fphar.2024.1410767","article-title":"Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"1471017","DOI":"10.3389\/fimmu.2024.1471017","article-title":"FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"112711","DOI":"10.1016\/j.intimp.2024.112711","article-title":"Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: a multi-center cohort study","volume":"139","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R28-20260109","first-page":"1222\u201330","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg Lond Engl"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"e7319","DOI":"10.1002\/cam4.7319","article-title":"Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: a longitudinal, multicenter study","volume":"13","author":"An","year":"2024","journal-title":"Cancer Med"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.eclinm.2022.101391","article-title":"Trajectories of serum \u03b1-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: a longitudinal, retrospective, multicentre, cohort study","volume":"47","author":"Lu","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R31-20260109","first-page":"437\u201340","article-title":"Improving screening for hepatocellular carcinoma by incorporating data on levels of \u03b1-fetoprotein, over time","volume":"11","author":"Lee","year":"2013","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"R32-20260109","first-page":"441\u201343","article-title":"\u03b1-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it","volume":"11","author":"El-Serag","year":"2013","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"219\u201328","DOI":"10.2147\/JHC.S432011","article-title":"A longitudinal study of AFP trajectories and clinical outcomes in intermediate-stage hepatocellular carcinoma after hepatectomy","volume":"11","author":"Yang","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"R34-20260109","first-page":"2429\u201338","article-title":"The inhibition of apoptosis by alpha-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence","volume":"14","author":"Laderoute","year":"1994","journal-title":"Anticancer Res"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:02:23Z","timestamp":1767963743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002818","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2025-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}